26.13
-0.40 (-1.51%)
| Previous Close | 26.53 |
| Open | 26.55 |
| Volume | 1,512,662 |
| Avg. Volume (3M) | 1,775,137 |
| Market Cap | 4,308,862,976 |
| Price / Earnings (TTM) | 12.44 |
| Price / Earnings (Forward) | 20.16 |
| Price / Sales | 2.96 |
| Price / Book | 2.70 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | 23.30% |
| Operating Margin (TTM) | 4.50% |
| Diluted EPS (TTM) | 2.10 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Quarterly Earnings Growth (YOY) | -39.00% |
| Total Debt/Equity (MRQ) | 4.90% |
| Current Ratio (MRQ) | 3.33 |
| Operating Cash Flow (TTM) | 516.83 M |
| Levered Free Cash Flow (TTM) | 429.53 M |
| Return on Assets (TTM) | 11.62% |
| Return on Equity (TTM) | 25.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Alkermes plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 2.38 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.49% |
| % Held by Institutions | 107.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (HC Wainwright & Co., 76.04%) | Hold |
| Median | 43.00 (64.56%) | |
| Low | 42.00 (RBC Capital, 60.74%) | Hold |
| 42.00 (UBS, 60.74%) | Buy | |
| Average | 43.60 (66.86%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 28.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 30 Jul 2025 | 42.00 (60.73%) | Hold | 27.93 |
| Needham | 29 Jul 2025 | 45.00 (72.22%) | Buy | 27.00 |
| 21 Jul 2025 | 45.00 (72.22%) | Buy | 26.66 | |
| HC Wainwright & Co. | 21 Jul 2025 | 46.00 (76.04%) | Hold | 26.66 |
| Goldman Sachs | 15 Jul 2025 | 43.00 (64.56%) | Buy | 28.85 |
| UBS | 17 Jun 2025 | 42.00 (60.73%) | Buy | 29.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jul 2025 | Announcement | Alkermes plc Reports Second Quarter 2025 Financial Results |
| 21 Jul 2025 | Announcement | Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 |
| 15 Jul 2025 | Announcement | Alkermes to Report Second Quarter Financial Results on July 29, 2025 |
| 02 Jun 2025 | Announcement | Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences |
| 02 Jun 2025 | Announcement | Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference |
| 29 May 2025 | Announcement | Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |